Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC.
Department of Pharmacy, Emory University Hospital Midtown, Atlanta, GA.
Am J Health Syst Pharm. 2021 Jan 1;78(1):49-59. doi: 10.1093/ajhp/zxaa342.
Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin administration. Management strategies are complex and include discontinuing heparin products, initiating alternative anticoagulants, interpreting laboratory test results, documenting heparin allergies, and providing patient education. Medication error reports and a retrospective review conducted at an academic medical center revealed an opportunity for a quality improvement initiative and led to the creation of a multidisciplinary workflow for the management of HIT. In a pre-post study, the impact of the multidisciplinary workflow on the safety and management of HIT was evaluated.
The preimplementation group consisted of adult patients tested for suspected HIT from April 4, 2014, through May 31, 2016; the postimplementation group consisted of adult patients tested from November 1, 2016, through October 31, 2018. The primary outcome was the incidence of heparin product administration while HIT testing was ongoing. The secondary outcome was the rate of appropriate heparin allergy documentation.
The incidence of heparin product administration while HIT testing results were pending was significantly reduced, from 54.2% to 20.0% (P < 0.001), after workflow implementation. The rate of appropriate heparin allergy documentation significantly increased, from 95.0% to 100% (P < 0.001).
Implementation of a multidisciplinary workflow for the management of HIT significantly reduced the incidence of heparin administration while testing was ongoing and improved the rate of appropriate heparin allergy documentation.
肝素诱导的血小板减少症(HIT)是肝素给药的严重并发症。管理策略较为复杂,包括停止肝素产品的使用、启动替代抗凝剂、解读实验室检测结果、记录肝素过敏情况并对患者进行教育。在一家学术医疗中心,药物错误报告和回顾性审查揭示了一个进行质量改进的机会,从而促成了 HIT 管理的多学科工作流程的建立。通过一项前后研究,评估了多学科工作流程对 HIT 安全性和管理的影响。
在实施前,纳入 2014 年 4 月 4 日至 2016 年 5 月 31 日期间因疑似 HIT 而接受检测的成年患者;在实施后,纳入 2016 年 11 月 1 日至 2018 年 10 月 31 日期间因疑似 HIT 而接受检测的成年患者。主要结局为在 HIT 检测期间继续使用肝素产品的发生率。次要结局为适当记录肝素过敏情况的比例。
实施工作流程后,在等待 HIT 检测结果时继续使用肝素产品的发生率从 54.2%显著降低至 20.0%(P<0.001)。适当记录肝素过敏情况的比例从 95.0%显著增加至 100%(P<0.001)。
HIT 管理的多学科工作流程的实施显著降低了在等待检测结果时继续使用肝素的发生率,并提高了适当记录肝素过敏情况的比例。